Market Morsels: QUB, API
On an incredibly slow news day Monday, here’s the latest from diversified logistics / infrastructure company Qube and chemist retailer Australian Pharmaceutical Industries.
Read MoreTag: API
All Systems Go for Wesfarmers’ API Bid
Wesfarmers’ takeover of Australian Pharmaceutical Industries has been given the greenlight to proceed after getting clearance from the competition regulator, the ACCC.
Read MoreWesfarmers Makes a Stand with API Holding
Wesfarmers’ decision yesterday not to sell its 19% stake in API is seen by most market pundits as effectively being a blocking move against the bid from rival Woolworths.
Read MoreWoolworths Gatecrashes API Party
Shares in API soared more than 16% on Thursday to a high of $1.74 after Woolworths crashed Wesfarmers’ attempt to take control of the company.
Read MoreTakeover Talk: SYD, SXY, API
Three deals advanced to the closing rounds of their respective games yesterday, involving Sydney Airport, Senex Energy and Australian Pharmaceutical Industries.
Read MoreShop Talk: COL, JBH, API
Not easy to make a dollar in the retail space over the past couple of years. Here’s how three of the majors are faring: Coles Group, JB Hi-Fi, and Australian Pharmaceutical Industries.
Read MoreAPI Primps and Preens for Suitors
API is making sure both its putative bidders understand how it is well it is performing at the moment with a surprise earnings upgrade ahead of the release of its full year results later this month.
Read MoreAPI Chessboard Moves to a Stalemate
Sigma’s attempt to snatch control of API appears to have been thwarted, with rival bidder Wesfarmers exercising its call option over 19.3% API shares to put it in a dominant blocking position.
Read MoreSigma Leapfrogs Wesfarmers in Race for API
Sigma Healthcare has come over the top of Wesfarmers and made a non-binding cash and share offer for rival chemist Australian Pharmaceutical Industries that seems to have grabbed the lead in the battle.
Read MoreWesfarmers Sweetens API Bid
Wesfarmers seems to have won the hearts and minds of the board and major shareholders of Australian Pharmaceutical Industries (API) with a lift in its proposed offer price from $1.38 cash to $1.55 a share.
Read MoreAPI Knocks Back “Opportunistic” Wesfarmers Bid
Australian Pharmaceutical Industries has told Wesfarmers to go away after rejecting the non-binding $1.38 a share offer as “opportunistic” and not in the best interests of shareholders.
Read MoreWesfarmers’ API Bid Could Put the Sector in Play
Wesfarmers’ surprise $687 million, $1.38 per share bid for Australian Pharmaceutical Industries (API) could very well re-ignite a brawl over the big retailers getting into the business.
Read MoreAPI Stuns Market with 30% Earnings Drop
Priceline chemist chain operator Australian Pharmaceutical Industries surprised on Thursday with a 30% slide in interim profit thanks to the impact of COVID shutdowns.
Read MoreStore Closures Hit API Bottom Line
Priceline Pharmacy owner Australian Pharmaceutical Industries expects first-half earnings from its retail operations to fall because of store closures in Melbourne and parts of Sydney in late 2020 and this month.
Read MoreLockdown Proves Bad Medicine For Australian Pharmaceutical Industries
The operator of the Priceline and Soul Pattinson pharmacy chain revealed a $7.9 million loss for the year to September 30, a result driven by the impact of lockdowns and other social distancing moves in the March to July periods, plus the later lockdown in Victoria.
Read MoreAust Pharma Suspends Dividend Amid “Relatively Low Growth”
Australian Pharmaceutical Industries, part of the group of companies clustered around Sydney-based Washington H Soul Pattinson, has dropped its interim dividend to shareholders as it prepares to face the gathering COVID-19 pandemic storm.
Read MoreAPI – Credit Suisse rates the stock as Underperform
The company has guided to a decline in underlying net profit in the first half because of challenging industry conditions that particularly affect the retail business. An improvement is expected in the second half.
Read MoreAPI – Credit Suisse rates the stock as Underperform
Australian Pharmaceutical has sold its 12.96% stake in Sigma Healthcare ((SIG)) for $0.60 a share. Credit Suisse calculates this represents a -$3.5m loss vs the price of the acquisition in December 2018.
Read More“Lumpy Week To Week”: Aust Pharma Closes Out Flat Year
Australian Pharmaceutical Industries – which owns the Priceline Pharmacy chain and is part-owned by Washington H Soul Pattinson has reported a modest rise in net after-tax profit for the year to August 31.
Read MoreAust Pharma Sweetens Shareholders After Failed Sigma Bid
Australian Pharmaceutical Industries (API) has lifted interim dividend 7.1% to 3.75 cents a share for the six months to February 28 after reported a steady underlying after-tax profit of $26.8 million.
Read MoreSigma Rebuffs Aust Pharma Takeover
Sigma Healthcare (SIG) shares slumped 15% at one stage yesterday after rejected a half-hearted takeover offer from rival Australian Pharmaceutical Industries (API).
Read MoreAust Pharma Edges Closer To Sigma Deal
Australian Pharmaceutical Industries is moving closer to embracing rival drug distributor, Sigma Healthcare.
Read MoreAust Pharma In New Push To Merge With Sigma
Australian Pharmaceutical Industries (API) has made a fresh push for a merger with the struggling Sigma Healthcare (SIP), revealing it had made a $700 million offer to Sigma’s board in October.
Read MoreAust Pharma Confirms Earnings Fall
Australian Pharmaceutical Industries has been warning of a weak performance in the year to September for the company and it duly delivered on that promise with an 8% fall in after-tax earnings.
Read MoreAust Pharma Warns On Weaker First-Half
Is this the first of what will be a string of bad news reports from listed retailers for the first half of 2017-18?
Read MoreClean Bill Of Health For Aust Pharma
Shares in Australian Pharmaceutical Industries jumped 4% yesterday as investors realised there were no shocks buried in the company’s 2016-17 annual results yesterday.
Read MoreAust Pharma Downgrades Profit Forecast
In contrast to the good update from Kathmandu, shares in Australian Pharmaceutical Industries took a hammering yesterday after it scaled back its estimated profit growth for 2016-17 to just 5%, half its previous guidance.
Read MoreAust Pharma To Roll Out More Priceline Stores
Australian Pharmaceutical Industries (API), which is one of the Sydney companies around Washington H Soul Pattinson, has completed what was an upbeat interim reporting season for the group.
Read MoreAPI In Good Health
As expected, Australian Pharmaceutical Industries Limited (API) met guidance in reporting underlying profit for the twelve months ended August 31 of $51.4 million up 18.0% on 2014-15.
Read MoreAPI Lifts Guidance
Shares in Australian Pharmaceutical Industries, owners of Priceline and other chemist chain, jumped more than 6% yesterday after it upgraded full-year profit guidance and revealed it had found a successor to long-standing chief executive Stephen Roche, who retires next February.
Read MoreAPI Back In The Black
Shares in wholesaler/retailer Australian Pharmaceutical Industries (API) fell yesterday after the company confirmed its return to profit and committed to the continued expansion of its network of Priceline stores.
Read MoreAPI Confident On Turnaround
Australian Pharmaceutical Industries (API) is now confident about boosting its performance in the 2014-15 year after cleaning up its accounts and taking a big bottom line loss in the year to August 31.
Read MoreMarket Loves API Upgrade
Investors just loved the earnings upgrade from Australian Pharmaceutical Industries (API), owners of a number of chemist chains including Priceline and Soul Pattinson.
Read MoreAPI Confirms Loss, Still Pays A Dividend
As expected, pharmacies supplier and retailer Australian Pharmaceutical Industries (API) has reported a whacking great loss for the first half of 2013-14 thanks to those big write offs announced just before Easter.
Read MoreAPI Shares Hold Up Despite Writedowns
Shares in Australian Pharmaceutical Industries (API) dipped 1.4% in yesterday’s stronger market as investors reassessed last Thursday’s announcement of big write downs in loan assets, but improved trading conditions.
Read MoreLosses Loom Over API
We can expect losses today from drugs wholesaler and pharmacies operator Australian Pharmaceutical Industries (API) which were placed in a trading halt yesterday ahead of an announcement by the company on the carrying value of its assets.
Read MoreAPI Top Of The Healthcare Pile
Australian Pharmaceutical Industries (API) stands at the top of the Australian healthcare sector simply by meeting guidance.
Read MoreAPI Weak, No One To Bid?
If Australian Pharmaceutical Industries thought it would soften the impact of a poor result by reporting the bare bones of the 2007 figures on Tuesday evening, it failed.
Read More
